Anti-microbial susceptibility pattern of spores used in Bacillus clausii suspension: an in vitro study


  • A. Srinivas Department of Probiotics R and D, Virchow Biotech Pvt, Ltd, Medchal II, Qutubullapur, Gagillapur, Hyderabad, Telangana, India



B. clausii, Probiotics, Resistance, Susceptibility


Background: Bacillus species have been used as probiotics as they have high stability to gastrointestinal conditions and impart health benefit on the host. Primarily used in their spore form the diversity of Bacillus species being used and their applications are remarkable. Here, we present the results of the antimicrobial susceptibility testing of the B. clausii spore suspension (Benegut®).

Methods: Bacillus clausii spore suspension (Benegut®), used in oral bacteriotherapy was tested for the susceptibility to therapeutically useful antibiotics. Twelve commercially prepared, paper antibiotic discs of different drugs having fixed concentrations were used.  The antimicrobial susceptibility test was performed by the disc diffusion technique, using soybean casein digestive agar (SCDA) as media and the results were categorized as susceptible, intermediate, or resistant; using the criteria published by the Clinical and Laboratory Standards Institute.

Results: B. clausii was found to be resistant to broad-spectrum antibiotic chloramphenicol, antimycobacterial rifampicin, beta-lactamase inhibitor amoxiclav, first-generation antibiotic cefaloridine, penicillin ampicillin, and tetracycline. B. clausii was resistant to both the aminoglycoside antibiotics (streptomycin and kanamycin) studied. Off first-generation fluoroquinolones studied, B. clausii was resistant to ciprofloxacin but partially sensitive to norfloxacin, ofloxacin and to macrolide azithromycin.   

Conclusions: Antimicrobial resistance is an important feature of probiotics. The results of our study indicate that the antimicrobial and immunomodulatory activity B. clausii spore suspension (Benegut®) can profess beneficial effects and can be a useful source of improving the intestinal imbalance of microbial flora and is safe for human consumption.


Guidelines for the Evaluation of Probiotics in Food. Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. 2002. [Cited December 30, 2019], Available at: Accessed on 30 December 2019.

Jozala AF, Geraldes DC, Tundisi LL, Feitosa VA, Breyer CA, Cardoso SL, et al. Biopharmaceuticals from microorganisms: from production to purification. Braz J Microbiol. 2016;47:51-63.

Doyle M.P, Steenson L.R, Meng J. Bacteria in Food and Beverage Production. In: Rosenberg E., DeLong E.F., Lory S., Stackebrandt E., Thompson F. (eds) The Prokaryotes; 2013:241-256.

Duc le H, Hong HA, Barbosa TM, Henriques AO, Cutting SM. Characterization of Bacillus Probiotics Available for Human Use. Appl Environ Microbiol. 2004;70:2161-71.

Hong HA, Duc le H, Cutting SM. The use of bacterial spore formers as probiotics. FEMS Microbiol Rev. 2005;29:813-35.

Abbrescia A, Palese LL, Papa S, Gaballo A, Alifano P, Sardanelli AM. Antibiotic Sensitivity of Bacillus clausii Strains in Commercial Preparation. Curr Med Chem. 2014;1:102-110.

Courvalin P. Antibiotic resistance: the pros and cons of probiotics. Dig Liver Dis. 2006;38(Suppl 2):S261-5.

Munita JM, Arias CA. Mechanisms of Antibiotic Resistance. Microbiol Spectr. 2016;4:1-4.

Imperial IC, Ibana JA; Addressing the Antibiotic Resistance Problem with Probiotics: Reducing the Risk of Its Double-Edged Sword Effect. Front Microbiol. 2016;7:1983.

Varankovich NV, Nickerson MT, Korber DR. Probiotic-based strategies for therapeutic and prophylactic use against multiple gastrointestinal diseases. Front Microbiol. 2015;6:685.

Rodloff A, Bauer T, Ewig S, Kujath P, Müller E. Susceptible, intermediate, and resistant - the intensity of antibiotic action. Dtsch Arztebl Int. 2008;105:657-62.

Gueimonde M, Sánchez B, de Los Reyes-Gavilán CG, Margolles A. Antibiotic resistance in probiotic bacteria. Front Microbiol 2013;4:202.

Khatri I, Sharma G, Subramanian S. Composite genome sequence of Bacillus clausii, a probiotic commercially available as Enterogermina®, and insights into its probiotic properties. BMC Microbiol. 2019;19:307.

Bozdogan B, Galopin S, Gerbaud G, Courvalin P, Leclercq R. Chromosomal aadD2 encodes an aminoglycoside nucleotidyltransferase in Bacillus clausii. Antimicrob Agents Chemother. 2003;47:1343-6.

Mazza P, Zani F, Martelli P. Studies on the antibiotic resistance of Bacillus subtilis strains used in oral bacteriotherapy. Boll Chim Farm. 1992;131:401-8.

Galopin S, Cattoir V, Leclercq R. A chromosomal chloramphenicol acetyltransferase determinant from a probiotic strain of Bacillus clausii. FEMS Microbiol Lett. 2009;296:185-9.

Senesi S, Celandroni F, Tavanti A, Ghelardi E. Molecular Characterization and Identification of Bacillus clausii strains marketed for use in oral bacteriotherapy. Appl Environ Microbiol. 2001;67: 834-9.

Zheng M, Zhang R, Tian X, Zhou X, Pan X, Wong A. Assessing the Risk of Probiotic Dietary Supplements in the Context of Antibiotic Resistance. Front Microbiol. 2017;8:908.

Girlich D, Leclercq R, Naas T, Nordmann P. Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. Antimicrob Agents Chemother. 2007;51:4009-14.

Imperial IC, Ibana JA. Addressing the Antibiotic Resistance Problem with Probiotics: Reducing the Risk of Its Double-Edged Sword Effect. Front Microbiol. 2016;7:1983.

Ianiro G, Rizzatti G, Plomer M, Lopetuso L, Scaldaferri F, Franceschi F, et al. Bacillus clausii for the Treatment of Acute Diarrhea in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. 2018;10. pii: E1074.

Marseglia GL, Tosca M, Cirillo I, Licari A, Leone M, Marseglia A, et al. Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: a pilot study. Ther Clin Risk Manag. 2007;3:13-7.

World Health Organization (WHO) Diarrhoeal Disease: Fact Sheet. Available at: Accessed on 10 February 2020.

Culligan EP, Hill C, Sleator RD. Probiotics and gastrointestinal disease: successes, problems and future prospects. Gut Pathog. 2009;1:19

Ghelardi E, Celandroni F, Salvetti S, Gueye SA, Lupetti A, Senesi S. Survival and persistence of Bacillus clausii in the human gastrointestinal tract following oral administration as spore-based probiotic formulation. J Appl Microbiol. 2015;119:552-9.

Elshaghabee FMF, Rokana N, Gulhane RD, Sharma C, Panwar H. Bacillus As Potential Probiotics: Status, Concerns, and Future Perspectives. Front Microbiol. 2017;8:1490.

Lakshmi SG, Jayanthi N, Saravanan M, Ratna MS. Safety assessment of Bacillus clausii UBBC07, a spore forming probiotic. Toxicol Rep. 2017;4:62-71.






Original Research Articles